UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory NoteDepomed Inc • June 10th, 2015 • Pharmaceutical preparations
On January 15, 2015, Depomed, Inc., a California corporation (“Depomed” or the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Janssen” or the “Seller”), pursuant to which Depomed would acquire from Janssen and its affiliates the U.S. rights to the NUCYNTA® franchise of pharmaceutical products (the “NUCYNTA® U.S. Product Rights”) as well as certain related assets (the “NUCYNTA® Acquisition”) for $1.05 billion in cash (the “Purchase Price”).
